229 related articles for article (PubMed ID: 25867045)
1. Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B.
Potts MB; McMillan EA; Rosales TI; Kim HS; Ou YH; Toombs JE; Brekken RA; Minden MD; MacMillan JB; White MA
Nat Chem Biol; 2015 Jun; 11(6):401-8. PubMed ID: 25867045
[TBL] [Abstract][Full Text] [Related]
2. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease.
Wilson RB; Chen YJ; Sutherland BG; Sawyez CG; Zhang R; Woolnough T; Hetherington AM; Peters KM; Patel K; Kennelly JP; Leonard KA; Schuurman M; Jacobs RL; Wang R; Borradaile NM
Pharmacol Res; 2020 Nov; 161():105208. PubMed ID: 32977024
[TBL] [Abstract][Full Text] [Related]
3. Treatment with didemnin B, an elongation factor 1A inhibitor, improves hepatic lipotoxicity in obese mice.
Hetherington AM; Sawyez CG; Sutherland BG; Robson DL; Arya R; Kelly K; Jacobs RL; Borradaile NM
Physiol Rep; 2016 Sep; 4(17):. PubMed ID: 27613825
[TBL] [Abstract][Full Text] [Related]
4. The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase.
Meng L; Sin N; Crews CM
Biochemistry; 1998 Jul; 37(29):10488-92. PubMed ID: 9671519
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of protein synthesis by didemnin B: how EF-1alpha mediates inhibition of translocation.
Ahuja D; Vera MD; SirDeshpande BV; Morimoto H; Williams PG; Joullié MM; Toogood PL
Biochemistry; 2000 Apr; 39(15):4339-46. PubMed ID: 10757982
[TBL] [Abstract][Full Text] [Related]
6. A Semisynthesis Platform for the Efficient Production and Exploration of Didemnin-Based Drugs.
Zhang H; Li X; Hui Z; Huang S; Cai M; Shi W; Lin Y; Shen J; Sui M; Lai Q; Shao Z; Dou J; Luo X; Ge Y; Tang X
Angew Chem Int Ed Engl; 2024 Mar; 63(12):e202318784. PubMed ID: 38291557
[TBL] [Abstract][Full Text] [Related]
7. Natural products as probes of cell biology: 20 years of didemnin research.
Vera MD; Joullié MM
Med Res Rev; 2002 Mar; 22(2):102-45. PubMed ID: 11857636
[TBL] [Abstract][Full Text] [Related]
8. Didemnin B induces apoptosis in proliferating but not resting peripheral blood mononuclear cells.
Baker MA; Grubb DR; Lawen A
Apoptosis; 2002 Oct; 7(5):407-12. PubMed ID: 12207173
[TBL] [Abstract][Full Text] [Related]
9. Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B.
Sánchez-Murcia PA; Cortés-Cabrera Á; Gago F
J Comput Aided Mol Des; 2017 Oct; 31(10):915-928. PubMed ID: 28900796
[TBL] [Abstract][Full Text] [Related]
10. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha.
Crews CM; Collins JL; Lane WS; Snapper ML; Schreiber SL
J Biol Chem; 1994 Jun; 269(22):15411-4. PubMed ID: 8195179
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of didemnin photoaffinity analogues.
Vera MD; Pfizenmayer AJ; Ding X; Ahuja D; Toogood PL; Joullié MM
Bioorg Med Chem Lett; 2001 Jul; 11(14):1871-4. PubMed ID: 11459650
[TBL] [Abstract][Full Text] [Related]
12. A Survey of Didemnin Depsipeptide Production in
Stankey RJ; Johnson D; Duggan BM; Mead DA; La Clair JJ
Mar Drugs; 2023 Jan; 21(2):. PubMed ID: 36827097
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25.
Johnson KL; Lawen A
Immunol Cell Biol; 1999 Jun; 77(3):242-8. PubMed ID: 10361256
[TBL] [Abstract][Full Text] [Related]
14. Bacterial biosynthesis and maturation of the didemnin anti-cancer agents.
Xu Y; Kersten RD; Nam SJ; Lu L; Al-Suwailem AM; Zheng H; Fenical W; Dorrestein PC; Moore BS; Qian PY
J Am Chem Soc; 2012 May; 134(20):8625-32. PubMed ID: 22458477
[TBL] [Abstract][Full Text] [Related]
15. Multiwavelength videomicrofluorometric study of cytotoxic effects of a marine peptide, didemnin B, on normal and MDR resistant CCRF-CEM cell lines.
Rocchi E; Vigo J; Viallet P; Bonnard I; Salmon JM
Anticancer Res; 2000; 20(2A):987-96. PubMed ID: 10810386
[TBL] [Abstract][Full Text] [Related]
16. Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described.
Grubb DR; Wolvetang EJ; Lawen A
Biochem Biophys Res Commun; 1995 Oct; 215(3):1130-6. PubMed ID: 7488040
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells.
Johnson KL; Vaillant F; Lawen A
FEBS Lett; 1996 Mar; 383(1-2):1-5. PubMed ID: 8612773
[TBL] [Abstract][Full Text] [Related]
18. Nannocystin A: an Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti-Cancer Properties.
Krastel P; Roggo S; Schirle M; Ross NT; Perruccio F; Aspesi P; Aust T; Buntin K; Estoppey D; Liechty B; Mapa F; Memmert K; Miller H; Pan X; Riedl R; Thibaut C; Thomas J; Wagner T; Weber E; Xie X; Schmitt EK; Hoepfner D
Angew Chem Int Ed Engl; 2015 Aug; 54(35):10149-54. PubMed ID: 26179970
[TBL] [Abstract][Full Text] [Related]
19. Abi Family Protein, DidK, Is Involved in the Maturation of Anticancer Depsipeptide, Didemnin B.
Jia K; Wang J; Zhai R; Du Y; Kira J; Wu C; Qian PY; Zhang W
ACS Chem Biol; 2023 Oct; 18(10):2300-2308. PubMed ID: 37773034
[TBL] [Abstract][Full Text] [Related]
20. A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.
Rebecca VW; Nicastri MC; McLaughlin N; Fennelly C; McAfee Q; Ronghe A; Nofal M; Lim CY; Witze E; Chude CI; Zhang G; Alicea GM; Piao S; Murugan S; Ojha R; Levi SM; Wei Z; Barber-Rotenberg JS; Murphy ME; Mills GB; Lu Y; Rabinowitz J; Marmorstein R; Liu Q; Liu S; Xu X; Herlyn M; Zoncu R; Brady DC; Speicher DW; Winkler JD; Amaravadi RK
Cancer Discov; 2017 Nov; 7(11):1266-1283. PubMed ID: 28899863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
